In the CY 2017 PFS final rule (81 FR 80272 through 80277), we responded in detail to several comments that we received regarding this issue
In addition, a wide array of interested parties recommended that CMS create a mechanism through which covered entities would retrospectively submit data to CMS identifying 340B claims dispensed under Part D
Retailers who try to set up tobacco shops on these platforms can have their accounts terminated within days of the first transaction, often with funds held for months
It was way better than this stuff, and I bet a lot more people would buy it
CMS is also considering an alternative policy whereby CMS would calculate the benchmark period manufacturer price for a new NDC-9 of an existing Part D rebatable drug that lacks AMP data for the time period described in 428.202(c)(1) or (2) using a reasonable proxy metric
This article has been viewed 1,888,709 times